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Abstract
‘Intracranial mesenchymal tumor, FET-CREB fusion-positive’ occurs primarily in children and young adults and has previously been termed intracranial
angiomatoid fibrous histiocytoma (AFH) or intracranial myxoid mesenchymal
tumor (IMMT). Here we performed genome-w ide DNA methylation array profiling of 20 primary intracranial mesenchymal tumors with FET-CREB fusion
to further study their ontology. These tumors resolved into two distinct epigenetic subgroups that were both divergent from all other analyzed intracranial
neoplasms and soft tissue sarcomas, including meningioma, clear cell sarcoma
of soft tissue (CCS), and AFH of extracranial soft tissue. The first subgroup
(Group A, 16 tumors) clustered nearest to but independent of solitary fibrous
tumor and AFH of extracranial soft tissue, whereas the second epigenetic subgroup (Group B, 4 tumors) clustered nearest to but independent of CCS and
also lacked expression of melanocytic markers (HMB45, Melan A, or MITF)
characteristic of CCS. Group A tumors most often occurred in adolescence
or early adulthood, arose throughout the neuroaxis, and contained mostly
EWSR1-ATF1 and EWSR1-CREB1 fusions. Group B tumors arose most often
in early childhood, were located along the cerebral convexities or spinal cord,
and demonstrated an enrichment for tumors with CREM as the fusion partner (either EWSR1-CREM or FUS-CREM). Group A tumors more often demonstrated stellate/spindle cell morphology and hemangioma-like vasculature,
whereas Group B tumors more often demonstrated round cell or epithelioid/
rhabdoid morphology without hemangioma-
like vasculature, although robust comparison of these clinical and histologic features requires future study.
Patients with Group B tumors had inferior progression-free survival relative to
Group A tumors (median 4.5 vs. 49 months, p = 0.001). Together, these findings
confirm that intracranial AFH-like neoplasms and IMMT represent histologic
variants of a single tumor type (‘intracranial mesenchymal tumor, FET-CREB
fusion-positive’) that is distinct from meningioma and extracranial sarcomas.
Additionally, epigenomic evaluation may provide important prognostic subtyping for this unique tumor entity.
K EY WOR DS
angiomatoid fibrous histiocytoma (AFH), ATF1, brain tumor, clear cell sarcoma, CREB1,
CREM, EWSR1, intracranial mesenchymal tumor with FET-CREB fusion, intracranial myxoid
mesenchymal tumor, molecular neuropathology, sarcoma
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I N T RODUC T ION

The newly recognized World Health Organization
(WHO) tumor type, ‘intracranial mesenchymal tumor,
FET-CREB fusion-positive’ [1], is a rare neoplasm of the
central nervous system (CNS) that has been previously
described as either intracranial angiomatoid fibrous histiocytoma or intracranial myxoid mesenchymal tumor
(IMMT) [2–5]. This tumor is molecularly defined by in-
frame gene fusion of the FET family of RNA-binding

proteins (EWSR1 or FUS) to the CREB (cyclic AMP
response element binding protein) family of transcription factors, which includes ATF1, CREB1, and CREM.
Notably, identical FET-CREB fusions are recurrently
found in angiomatoid fibrous histiocytoma (AFH), clear
cell sarcoma of soft tissue (CCS), clear cell sarcoma of
the gastrointestinal tract, primary pulmonary myxoid
sarcoma, hyalinizing clear cell carcinoma of the salivary
gland, and a subset of malignant mesotheliomas lacking
BAP1 and NF2 alterations [6–16]. However, the exact
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relationship of these intracranial mesenchymal tumors
with FET-CREB fusions to AFH of extracranial soft tissue and other FET-CREB fusion-driven neoplasms has
been uncertain.
We previously studied the clinical, radiologic, histologic, and genomic features of a cohort of 20 intracranial
mesenchymal tumors with FET-CREB fusions [5]. We
identified that these tumors occur with a female predominance (approximately 2:1 female/male ratio) in a wide
age range, but most often occur in the second and third
decades of life. They are predominantly extra-axial or
intraventricular tumors which can arise throughout the
neuroaxis, including the falx, tentorium, cerebral convexities, and lateral ventricles. They are typically contrast enhancing masses, well-circumscribed, with solid and cystic
growth patterns, and often have pronounced peritumoral
edema. Beyond the oncogenic FET-CREB fusions, they
typically lack accompanying oncogenic mutations, amplifications, or deletions, and usually harbor near-diploid
genomes. These tumors are associated with a propensity
for local recurrence over time, but only a small subset
have disseminated and resulted in patient mortality.
Here we have performed genome-w ide DNA methylation profiling on our previously published cohort of 20
primary intracranial mesenchymal tumors with FET-
CREB fusions to further study the ontology of these
neoplasms and identify any clinically relevant epigenetic
subgroups.
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to Infinium EPIC 850k Human DNA Methylation
BeadChips following the manufacturer's recommended
protocol (Illumina).

2.3 | Processing and quality assessment of
DNA methylation data
Methylation data were preprocessed using the minfi
package (v.1.30.0) in R Bioconductor (version 3.5.3) [17].
The detection p-value for each sample was computed,
and CpG sites with detection p values above 0.05 were
discarded from the analysis. Additional quality control
was performed by calculating the median log (base2)
intensities for methylated and unmethylated signals for
each array. All samples had unmethylated and methylated median intensity values above 10 that were used
for analysis. Functional normalization with NOOB
background correction and dye-
bias normalization
was performed [18, 19]. Probe filtering was performed
after normalization. Specifically, probes located on sex
chromosomes, containing nucleotide polymorphisms
(dbSNP132 Common) within five base pairs of and including the targeted CpG site, or mapping to multiple
sites on hg19 (allowing for one mismatch), as well as cross
reactive probes were removed from analysis.

2.4 | Unsupervised hierarchical clustering of
DNA methylation data

We performed unsupervised hierarchical clustering with
the hclust function in Rstats (v3.6.0) to assess variation
in DNA methylation patterns and determine any relThe study cohort consisted of 20 patients who underwent
evant epigenetic subgrouping among the 20 tumors. The
surgical resection of a primary intracranial neoplasm
lmFit function from the Limma package (v.3.40.6) was
that was identified to harbor a gene fusion of EWSR1 or
applied on a log-transformed β-value matrix to identify
the related FUS together with a CREB family member
the 20,000 most differentially methylated CpG probes
(ATF1, CREB1, or CREM). The clinical features of these
across the tumor cohort. Then K-means clustering uti20 patients and histopathologic features of the tumor colizing the Pearson distance matrix with complete linkage
hort were previously reported [5].
was used to determine the optimal number of clusters,
through 500 re-sampling interactions of the dataset for
K-means of 2, 3, 4, or 5. Visualization was performed
using the R package ComplexHeatmap (v.2.0.0) [20].
2.2 | Genome-wide DNA
We also compared the DNA methylation patterns
methylation profiling
of the 20 intracranial mesenchymal tumors with FET-
CREB fusion against the DNA methylation patterns of
Tumor tissue was selectively scraped from unstained
slides or punched from formalin-
f ixed, paraffin- two extracranial sarcoma entities with identical FET-
CREB fusions (clear cell sarcoma of soft tissue and
embedded (FFPE) blocks using 2.0 mm disposable biangiomatoid fibrous histiocytoma) that we recently genopsy punches (Integra Miltex Instruments) to enrich for
erated as part of our development of the DKFZ Sarcoma
the highest tumor content possible. Genomic DNA was
Methylation Classifier (www.molecularsarcomapath
extracted from this macrodissected tumor tissue using
ology.org) [21]. This included 7 reference cases of clear
the QIAamp DNA FFPE Tissue Kit (Qiagen). Genomic
cell sarcoma of soft parts (tumor ID’s: 956, 957, 958, 959,
DNA was bisulfite converted using the EZ DNA
960, 961, and 962), which were all located in the soft tisMethylation kit following the manufacturer's recomsue of the upper or lower extremities with median pamended protocol (Zymo Research). Bisulfite converted
tient age of 56 years (range 18–78 years). Also included
DNA was then amplified, fragmented, and hybridized

2.1 | Study population and tumor specimens
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were 8 reference cases of angiomatoid fibrous histiocytoma (tumor ID’s: 340, 341, 360, 361, 362, 363, 364, 1066),
which were all located in extracranial soft tissue with
median patient age of 11 years (range 6–13 years). The
lmFit function from the Limma package (v.3.40.6) was
applied on a log-transformed β-value matrix to identify
the 20,000 most differentially methylated CpG probes
across the cohort of 20 intracranial mesenchymal tumors
with FET-CREB fusion together with the 7 reference
cases of clear cell sarcoma of soft parts and 8 reference
cases of angiomatoid fibrous histiocytoma of extracranial soft tissue. K-means clustering utilizing the Pearson
distance matrix with complete linkage was then used to
determine the optimal number of clusters, through 500
re-sampling interactions of the dataset for K-means of
2, 3, 4, or 5. Unsupervised hierarchical clustering of
DNA methylation data was performed using the hclust
function in Rstats (v3.6.0). Visualization was performed
using the R package ComplexHeatmap (v.2.0.0).

2.5 | tSNE dimensionality reduction of DNA
methylation data
The DNA methylation profiles of the 20 intracranial mesenchymal tumors with FET-CREB fusions were assessed
together with 210 reference tumors spanning 17 sarcoma
and CNS tumor entities previously generated at DKFZ
[21, 22], which were selected based on tumor types with
a similar meningeal/extra-axial location, tumor types
that might enter into the differential diagnosis based
on overlapping morphologic appearance, and extracranial sarcomas driven by EWSR1 or FUS gene fusions.
These included 10 angiomatoid fibrous histiocytoma of
extracranial soft tissue, 30 atypical teratoid/rhabdoid
tumor (belonging to the three different epigenetic subgroups: MYC, SHH, and TYR), 10 clear cell sarcoma of
soft tissue, 10 chordoma, 10 extraskeletal myxoid chondrosarcoma, 10 H3 K27M-mutant diffuse midline glioma, 10 desmoplastic small round cell tumor, 10 Ewing
sarcoma, 10 IDH-w ildtype glioblastoma of the mesenchymal epigenetic subclass, 10 low-g rade fibromyxoid
sarcoma, 30 meningioma (belonging to the various
epigenetic subgroups), 10 alveolar rhabdomyosarcoma,
10 embryonal rhabdomyosarcoma, 10 CIC-altered sarcoma, 10 DICER1-mutant sarcoma, 10 solitary fibrous
tumor, and 10 synovial sarcoma. Since the reference
cohort contained methylation data generated using the
Infinium Human Methylation 450k BeadChips, the approximately 450,000 overlapping CpG sites between the
EPIC 850k and 450k BeadChips were used in the analysis. A beta value matrix with approximately 390,000
CpG probes was used for all downstream analysis. Row-
wise standard deviation was calculated for each probe
across all samples, and the 20,000 most differentially
methylated probes with standard deviation >0.216 were
selected. Dimensionality reduction using t-distributed
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stochastic neighbor embedding (tSNE) was performed
by Rtsne (v.0.15) using the following analysis parameters:
dims = 2, max_iter = 3000, theta = 0, perplexity = 20,
eta = 200. The tSNE plot was visualized with ggplot2
(v.3.2.0) [https://ggplot2.tidyverse.org/].

2.6 | Differentially methylated region and
gene ontology analysis
Differentially methylated regions (DMRs) between epigenetic tumor classes were identified using DMRcate
(v.1.20.0) [23], which ranks the most differentially methylated genomic regions using gaussian smoothing across
adjacent CpG sites. For DMRcate, a model with coefficients using the following parameters and thresholds was
created: lambda (genomic window length) = 1000 nucleotides, C (scaling factor) = 2, and probe false discovery
rate (FDR) cutoff of less than 0.05. Results were ranked
by Fisher's multiple comparison statistic and filtered for
those DMRs with both FDR and Stouffer scores less
than 0.001. DMRs were then annotated to the nearest
gene transcriptional start sites, based on ENSEMBL genome annotations. Gene Ontology (GO) analysis of differentially methylated gene regions was performed using
the gometh function in the missMethyl package [24].

2.7 | Immunohistochemistry
Immunohistochemistry was performed on whole
formalin-
f ixed, paraffin-
embedded tissue sections
using the following antibodies: desmin (Cell Marque,
clone D33, undiluted, ER1 antigen retrieval), epithelial
membrane antigen (EMA, Leica, clone GP1.4, undiluted, ER1 antigen retrieval), CD99 (Signet, clone CD99,
1:400 dilution, ER1 antigen retrieval), S100 (DAKO,
polyclonal, 1:2000 dilution, no antigen retrieval), MUC4
(Millipore, clone 8G7, 1:500 dilution, ER1 antigen retrieval), somatostatin receptor 2A (SSTR2A, Abcam,
clone UMB1, 1:2000 dilution, ER2 antigen retrieval),
OLIG2 (Immuno Bio Labs, polyclonal, 1:200 dilution,
ER1 antigen retrieval), glial fibrillary acidic protein
(GFAP, DAKO, polyclonal, 1:3000 dilution, no antigen
retrieval), synaptophysin (Cell Marque, polyclonal, 1:100
dilution, ER2 antigen retrieval), CD68 (Leica, clone
514H12, undiluted, ER2 antigen retrieval), cytokeratin
AE1/AE3 (Dako, clone AE1/AE3, 1:100 dilution, ER1 antigen retrieval), cytokeratin CAM5.2 (Becton Dickinson,
clone CAM5.2, 1:100 dilution, ER1 antigen retrieval),
HMB45 (Dako, clone HMB45, undiluted, CC1 antigen
retrieval), Melan A (Dako, clone A103, 1:10 dilution,
ER1 antigen retrieval), MITF (Dako, clone D5, 1:200 dilution, ER1 antigen retrieval), myogenin (Cell Marque,
clone F5D, undiluted, CC1 antigen retrieval), and Ki-67
(Dako, clone Mib1, 1:50 dilution, ER2 antigen retrieval).
Immunostaining for desmin, EMA, CD99, S100, MUC4,

INTRACRANIAL MESENCHYMAL TUMOR, FET-CREB FUSED

SSTR2A, OLIG2, GFAP, synaptophysin, CD68, cytokeratin AE1/AE3, cytokeratin CAM5.2, Melan A,
MITF, and Ki-67 was performed in a Leica BOND-III
automated stainer. Immunostaining for HMB45 and myogenin was performed in a Ventana BenchMark Ultra
automated stainer. Diaminobenzidine was used as the
chromogen, followed by hematoxylin counterstain.

2.8 | Kaplan-Meier survival plots and
statistical analyses
Clinical outcomes were studied by Kaplan-Meier analysis using GraphPad Prism. The Kaplan-Meier survival
analysis was stratified by epigenetic subgroup, and
p value was calculated by Log-rank (Mantel-Cox) test.
Statistical comparison of histologic and immunohistochemical features was performed by Mann-W hitney
unpaired two-tailed t test using GraphPad Prism.
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R E SU LT S

3.1 | DNA methylation profiling reveals two
epigenetic subgroups
We performed genome-w ide DNA methylation profiling on our previously published cohort of 20 primary
intracranial mesenchymal tumors with FET-CREB fusions. The clinical and radiologic features of these 20
patients and the histopathologic and genomic features
of the tumor cohort were previously reported in open access format – https://onlinelibrary.wiley.com/doi/10.1111/
bpa.12918 [5]. Unsupervised hierarchical clustering of
the DNA methylation profiles segregated these tumors
into two epigenetically distinct subgroups: Group A consisting of 16 tumors and Group B consisting of 4 tumors
(Figure 1A and Table 1).

3.2 | Clinical and molecular
characteristics of the two epigenetic subgroups
Group A tumors were from 11 females and 5 males
with a median age at diagnosis of 15 years (range 12–
70 years) (Tables 1 and 2, Figure 1B). The tumors were
located throughout the neuroaxis, including the cerebral
convexities (n = 4), tentorium (n = 2), falx (n = 2), lateral ventricles (n = 4), and cerebellopontine angle (n = 4)
(Figure 1C). Fusion partners were EWSR1-ATF1 (n = 7),
EWSR1-CREB1 (n = 7), and EWSR1-CREM (n = 2)
(Figure 1D). The 4 Group B tumors were exclusively
from females with a median age at diagnosis of 7 years
(range 4–15 years). The tumors were located along the
cerebral convexities (n = 3) or spinal cord (n = 1). Fusion
partners were EWSR1-ATF1 (n = 1), EWSR1-CREM
(n = 2), and FUS-CREM (n = 1). As previously reported,
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these tumors all had near-diploid genomes [5], and we
did not observe any recurrent chromosomal copy number changes among either epigenetic subgroup.

3.3 | Differential gene methylation analysis
between two epigenetic subgroups
We next determined all differentially methylated genomic
regions (DMR) with a mean beta value difference of at
least 0.3 between the two epigenetic subgroups, which
yielded nearly 1100 such DMR (Tables S1 and S2). Gene
Ontology analysis of the most differentially methylated
genes between the two epigenetic subgroups revealed
networks involved in Rho GTPase signaling (Figure 1E,
Table S3), a pathway known to control cell growth, motility, and actin cytoskeletal remodeling.

3.4 | Histologic and immunophenotypic
features of the two epigenetic subgroups
We have previously described the wide morphologic
spectrum of intracranial mesenchymal tumors with
FET-CREB fusion, ranging from stellate/spindle cell to
epithelioid/rhabdoid cytology along with variable stromal mucin content and hemangioma-like vasculature [5].
When comparing histologic features between the two
epigenetic subgroups, no statistically significant differences were apparent (Figure 2, Table 3). The presence of
a myxoid stroma did not strictly correlate with the epigenetic subgroups –11/16 (69%) of the Group A tumors and
1/4 (25%) of the Group B tumors demonstrated a mucin-
rich stroma. Hemangioma-like vasculature was only encountered in the Group A tumors (10/16 [63%]). Stellate/
spindle cell cytomorphology was also only encountered
in Group A tumors (10/16 [63%]).
The Ki-67 labeling index in this tumor cohort was
generally low (less than 5%, 8 of the 15 evaluated tumors), but occasionally was elevated up to 15%–25% (7
of the 15 evaluated tumors) [5]. There was no significant
difference in Ki-67 labeling index between the two epigenetic subgroups, though three of the four Group B tumors were those with elevated Ki-67 labeling index.
We also examined for any differences in immunophenotype between the two epigenetic subgroups (Table 4).
Desmin, EMA, CD99, and CD68 expression was nearly
ubiquitous among all tumors belonging to both subgroups, and MUC4 and synaptophysin expression was
also frequent in both subgroups. Among the seven
Group A tumors evaluated for MUC4 expression, three
demonstrated diffuse strong staining, one demonstrated
focal positivity, and two were negative. Among the four
Group B tumors evaluated for MUC4 expression, three
demonstrated focal positivity and one was negative.
Among the seven Group A tumors evaluated for synaptophysin expression, three demonstrated patchy variable
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F I G U R E 1 ‘Intracranial mesenchymal
tumor, FET-CREB fusion-positive’ is
composed of two distinct epigenetic
subgroups. (A) Unsupervised hierarchical
clustering of DNA methylation data from
20 intracranial mesenchymal tumors with
FET-CREB fusion showing segregation
into two epigenetic subgroups –Group
A consisting of 16 tumors and Group B
consisting of 4 tumors. Differentially
methylated genomic regions between the
two subgroups are annotated in Tables
S1 and S2. (B) Dot plot of patient age at
diagnosis stratified by epigenetic subgroup.
(C). Dot plot of tumor anatomic location
stratified by epigenetic subgroup. (D) Dot
plot of fusion type stratified by epigenetic
subgroup. (E). Differential methylation-
based gene ontology analysis for the
two epigenetic subgroups of intracranial
mesenchymal tumors with FET-CREB
fusion, represented in a bar plot of −
log10 p values for the most differentially
methylated gene networks

intensity staining while the other four were negative.
Both of the two Group B tumors evaluated for synaptophysin expression demonstrated patchy variable intensity staining. None of the examined tumors belonging to
either subgroup was positive for somatostatin receptor
2A (SSTR2A) expression or markers of melanocytic differentiation (MITF, Melan A, and HMB45). None of the
investigated proteins had significantly different expression levels between Group A and Group B tumors, and
further studies are necessary to identify potential immunohistochemical surrogates for segregating the two epigenetic subgroups.

3.5 | Clinical outcomes of the two
epigenetic subgroups
The complete clinical data including extent of resection,
treatment regimen, and outcome data from the twenty
patients were previously reported [5]. Kaplan-
Meier
analysis of progression-free survival (PFS) stratified by

epigenetic subgroup revealed inferior outcomes of Group
B tumors relative to Group A tumors (median PFS of 4.5
vs. 49 months, p = 0.001) (Figure 3). Only three of the
20 patients succumbed to disease during the period of
clinical follow-up, all of whom harbored EWSR1-ATF1
fusions, of which two (ATF1 #6 and ATF1 #7) belonged
to Group A and one (ATF1 #2) belonged to Group B.
Kaplan-Meier analysis of overall survival stratified by
epigenetic subgroup did not reveal a significant difference (data not shown).

3.6 | Epigenetic comparison with other CNS
tumor entities and extracranial sarcomas
We next performed tSNE dimensionality reduction of
the DNA methylation profiles for the 20 intracranial
mesenchymal tumors with FET-CREB fusion together
with 210 reference tumors spanning 17 sarcoma and CNS
tumor entities previously generated at DKFZ [21, 22]
(Table S4). The intracranial mesenchymal tumors with
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T A B L E 1 Clinical characteristics, tumor histopathologic features, and epigenetic subgroup for the 20 patients with ‘intracranial
mesenchymal tumor, FET-CREB fusion-positive'
Mucin-rich
stroma

Predominant morphology

Fusion type

Epigenetic
subgroup

Cerebral convexity
(parietal)

No

Epithelioid/rhabdoid

EWSR1-ATF1

Group A

F

Cerebral convexity
(occipital)

Yes

Epithelioid/rhabdoid

EWSR1-ATF1

Group A

13

F

Cerebral convexity
(frontal)

Yes

Stellate/spindled

EWSR1-ATF1

Group A

ATF1 #5

34

F

Tentorium

No

Epithelioid/rhabdoid

EWSR1-ATF1

Group A

ATF1 #6

17

F

CP angle

No

Epithelioid/rhabdoid

EWSR1-ATF1

Group A

ATF1 #7

70

M

CP angle with spinal
dissemination

No

Epithelioid/rhabdoid

EWSR1-ATF1

Group A

ATF1 #8

17

F

CP angle

No

Epithelioid/rhabdoid

EWSR1-ATF1

Group A

CREB1 #1

14

F

Lateral ventricle

Yes

Stellate/spindled

EWSR1-CREB1

Group A

CREB1 #2

39

F

Lateral ventricle

Yes

Stellate/spindled

EWSR1-CREB1

Group A

Patient ID

Age

Sex

Tumor location

ATF1 #1

12

M

ATF1 #3

24

ATF1 #4

CREB1 #3

10

M

Falx (parietal)

Yes

Stellate/spindled

EWSR1-CREB1

Group A

CREB1 #4

14

F

Lateral ventricle

Yes

Stellate/spindled

EWSR1-CREB1

Group A

CREB1 #5

25

F

CP angle

Yes

Stellate/spindled

EWSR1-CREB1

Group A

CREB1 #6

14

F

Cerebral convexity
(parietal)

Yes

Stellate/spindled

EWSR1-CREB1

Group A

CREB1 #7

12

M

Tentorium

Yes

Stellate/spindled

EWSR1-CREB1

Group A

CREM #2

14

F

Lateral ventricle

Yes

Stellate/spindled

EWSR1-CREM

Group A

CREM #4

30

M

Falx (frontal)

Yes

Stellate/spindled

EWSR1-CREM

Group A

ATF1 #2

9

F

Cerebral convexity
(frontal)

Yes

Round cell

EWSR1-ATF1

Group B

CREM #1

15

F

Spinal cord (thoracic)

No

Epithelioid/rhabdoid

EWSR1-CREM

Group B

CREM #3

5

F

Cerebral convexity
(frontal)

No

Round cell

EWSR1-CREM

Group B

FUS #1

4

F

Cerebral convexity
(occipital)

No

Epithelioid/rhabdoid

FUS-CREM

Group B

FET-CREB fusion resolved into two distinct epigenetic
subgroups that were both divergent from all other analyzed intracranial neoplasms and soft tissue sarcomas,
including meningioma, Ewing sarcoma, extraskeletal
myxoid chondrosarcoma, clear cell sarcoma of soft tissue (CCS), and AFH of extracranial soft tissue (Figure 4,
top panel). The two epigenetic subgroups identified by
unsupervised hierarchical clustering (Figure 1A) were recapitulated by the tSNE dimensionality reduction analysis, with the same 16 tumors aligning with Group A and
same 4 tumors aligning with Group B by both analyses
(Figure 4, bottom panel). The Group A tumors clustered
nearest to but independent of solitary fibrous tumor and
AFH of extracranial soft tissue, whereas the Group B
tumors clustered nearest to but independent of CCS and
the mesenchymal subclass of IDH-
w ildtype glioblastoma. By random forest classification using both the
online DKFZ Sarcoma Classifier tool version 12.2 and
the online DKFZ Brain Tumor Classifier tool version
11b4, only 3 of the 16 Group A tumors aligned with the
methylation class “Angiomatoid fibrous histiocytoma”

with a calibrated score of greater than 0.9, whereas the
remainder of the 13 tumors did not reliably classify as
“Angiomatoid fibrous histiocytoma” or any other reference methylation class of sarcoma or CNS tumor (Table
S5). None of the 4 Group B tumors reliably classified as
“Angiomatoid fibrous histiocytoma”, “Clear cell sarcoma of soft tissue”, or any other reference methylation
class of sarcoma or CNS tumor (Table S5).
We next further compared the DNA methylation patterns of the 20 intracranial mesenchymal tumors with
FET-
CREB fusion against two extracranial sarcoma
entities with identical FET-CREB fusions (clear cell sarcoma of soft tissue and angiomatoid fibrous histiocytoma) that were recently generated as part of the DKFZ
Sarcoma Methylation Classifier [21]. Unsupervised hierarchical clustering was performed on the 16 Group A
tumors together with 8 reference cases of angiomatoid
fibrous histiocytoma, which were all located in extracranial soft tissue with a median patient age of 11 years
(range 6–13 years). This unsupervised clustering analysis segregated the 24 total tumors into two groups
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–one composed of the 16 Group A tumors and the
other composed of the 8 AFH of extracranial soft tissue
(Figure 5A). We next determined all differentially methylated genomic regions (DMR) with a mean beta value
T A B L E 2 Clinical features of the 20 patients with ‘intracranial
mesenchymal tumor, FET-CREB fusion-positive’ stratified by
epigenetic subgroup
Clinical features

All
tumors

Group A

Group B

Median

15

7

14

Range

12–70

4–15

4–70

Male

5

0

5

Female

11

4

15

Cerebral convexity

4

3

7

Tentorium

2

0

2

Falx

2

0

2

Lateral ventricle

4

0

4

CP angle

4

0

4

Spinal cord

0

1

1

EWSR1-ATF1

7

1

8

EWSR1-CREB1

7

0

7

EWSR1- CREM

2

2

4

FUS- CREM

0

1

1

Age at diagnosis (years)

Sex

Tumor location

Fusion type

difference of at least 0.3 between the Group A intracranial mesenchymal tumors and AFH of extracranial
soft tissue, which yielded nearly 600 such DMR (Tables
S6 and S7). Gene Ontology analysis of the most differentially methylated gene regions between the Group A
tumors and AFH of extracranial soft tissue revealed
networks involved in muscle structure development and
axial mesoderm formation (Figure 5B, Table S8).
Unsupervised hierarchical clustering was also performed on the 4 Group B tumors together with 7 reference
cases of clear cell sarcoma, which were all located in the
soft tissue of the upper or lower extremities with median
patient age of 56 years (range 18–78 years). This unsupervised clustering analysis segregated the 11 total tumors
into two groups –one composed of the 4 Group B tumors and the other composed of the 7 clear cell sarcomas
(Figure 6A). The one intracranial mesenchymal tumor
with EWSR1-CREM fusion (CREM #1) that clustered
somewhat nearer to CCS than the other three Group B
tumors on tSNE dimensionality reduction segregated
together with the Group B tumors and not CCS by this
unsupervised hierarchical clustering analysis. We next
determined all differentially methylated genomic regions
(DMR) with a mean beta value difference of at least 0.3
between the Group B intracranial mesenchymal tumors
and CCS of soft tissue, which yielded nearly 700 such
DMR (Tables S9 and S10). One of the most differentially
methylated genomic regions was the MITF gene, which
was substantially hypermethylated in the Group B intracranial mesenchymal tumors versus hypomethylated/
unmethylated in the CCS tumors (Figure 6B). MITF
encodes the microphthalmia-
associated transcription

F I G U R E 2 Histologic features of
intracranial mesenchymal tumors with
FET-CREB fusion belonging to the
two epigenetic subgroups. Hematoxylin
and eosin-stained sections from three
representative tumors of the two epigenetic
subgroups
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T A B L E 3 Histologic features of
‘intracranial mesenchymal tumor,
FET-CREB fusion-positive’ stratified by
epigenetic subgroup

Histologic feature

Group A

Group B

|
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All tumors

Mucin-r ich stroma

11/16 (69%)

1/4 (25%)

12/20 (60%)

Collagenous stroma –intercellular
matrix

16/16 (100%)

4/4 (100%)

20/20 (100%)

Collagenous stroma –internodular
septae

12/16 (75%)

2/4 (50%)

14/20 (70%)

Epithelioid/rhabdoid morphology

8/16 (50%)

2/4 (50%)

10/20 (50%)

10/16 (63%)

0/4 (0%)

10/20 (50%)

0/16 (0%)

2/4 (50%)

2/20 (10%)

10/16 (63%)

0/4 (0%)

10/20 (50%)

Stellate/spindle cell morphology
Round cell morphology
Hemangioma-l ike vasculature
Staghorn/HPC-l ike vasculature

3/16 (19%)

1/4 (25%)

4/20 (20%)

Pseudoangiomatous spaces

0/16 (0%)

0/4 (0%)

0/20 (0%)

Dense lymphoplasmacytic cuffing

11/16 (69%)

1/4 (25%)

12/20 (60%)

Hemosiderin/hematoidin

10/16 (63%)

3/4 (75%)

13/20 (65%)

Meningioma-l ike whorls

4/16 (25%)

0/4 (0%)

4/20 (20%)

Amianthoid fibers

2/16 (13%)

0/4 (0%)

2/20 (10%)

Necrosis

1/16 (6%)

1/4 (25%)

2/20 (10%)

T A B L E 4 Immunohistochemical features of ‘intracranial
mesenchymal tumor, FET-CREB fusion-positive’ stratified by
epigenetic subgroup
Protein marker

Group A

Group B

All tumors

Desmin

14/14 (100%)

3/3 (100%)

17/17 (100%)

EMA

13/14 (93%)

3/3 (100%)

16/17 (94%)

CD99

8/8 (100%)

2/2 (100%)

10/10 (100%)

CD68

7/8 (88%)

1/1 (100%)

8/9 (89%)

MUC4

4/7 (57%)

3/4 (75%)

7/11 (64%)

Synaptophysin

3/7 (43%)

2/2 (100%)

5/9 (56%)

S100

6/13 (46%)

1/4 (25%)

7/17 (41%)

SOX10

0/6 (0%)

1/4 (25%)

1/10 (10%)

MelanA

0/2 (0%)

0/4 (0%)

0/6 (0%)

HMB45

0/4 (0%)

0/4 (0%)

0/8 (0%)

MITF

0/1 (0%)

0/4 (0%)

0/5 (0%)

Myogenin

0/6 (0%)

0/2 (0%)

0/8 (0%)

SSTR2a

0/7 (0%)

0/2 (0%)

0/9 (0%)

GFAP

0/10 (0%)

0/2 (0%)

0/12 (0%)

Cytokeratin AE1/
AE3

1/10 (10%)

0/1 (0%)

1/11 (9%)

Cytokeratin
CAM5.2

0/11 (0%)

0/2 (0%)

0/13 (0%)

factor on chromosome 3p13 that functions as a critical
transcription factor for specifying melanocytic differentiation, and is robustly expressed in clear cell sarcoma
of soft tissue (formerly referred to as melanoma of soft
parts) that is pathologically defined by its expression
of melanocytic markers including MITF, HMB45, and
Melan A [25, 26]. In contrast to CCS, we found an absence
of MITF expression by immunohistochemical staining
in all four of the Group B intracranial mesenchymal

F I G U R E 3 Kaplan-Meier plot of progression-free survival for
patients with intracranial mesenchymal tumor, FET-CREB fusion-
positive stratified by epigenetic subgroup

tumors with FET-CREB fusion, as well as other melanocytic markers (Figure 6C). In addition to MITF, Gene
Ontology analysis of the most differentially methylated
gene regions between Group B intracranial mesenchymal tumors and CCS of soft tissue revealed networks involved in roof of mouth development and embryonic eye
development (Figure 6D, Table S11).

4
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DI SC US SION

Here we have interrogated the epigenomic landscape
of intracranial mesenchymal tumors harboring FET-
CREB fusion and correlated the results together with
clinical and histopathologic features. Our findings reveal
that these tumors segregate into two discrete epigenetic
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F I G U R E 4 tSNE dimensionality
reduction plot of genome-w ide DNA
methylation profiles from the 20
intracranial mesenchymal tumors with
FET-CREB fusion alongside 210 reference
tumors spanning 17 sarcoma and CNS
tumor entities previously generated at
DKFZ. See Table S4 for tSNE sample
manifest. AT/RT, atypical teratoid/
rhabdoid tumor. DMG, diffuse midline
glioma. DSRCT, desmoplastic small
round cell tumor. GBM, glioblastoma.
LGFMS, low-g rade fibromyxoid sarcoma.
SFT/HPC, solitary fibrous tumor/
hemangiopericytoma

subgroups which we have termed Group A and Group
B. Group A tumors most often occurred in adolescence
or early adulthood, arose throughout the neuroaxis, and
consisted of a mix of EWSR1-ATF1, EWSR1-CREB1,
and EWSR1-CREM fusions. Group B tumors arose
most often in early childhood, were located along the
cerebral convexities or spinal cord, and demonstrated an
enrichment for tumors with CREM as the fusion partner (either EWSR1-CREM or FUS-CREM). Group A
tumors more often demonstrated stellate/spindle cell
morphology and hemangioma-like vasculature, whereas
Group B tumors more often demonstrated round cell or
epithelioid/rhabdoid morphology without hemangioma-
like vasculature, although these differences did not
reach statistical significance. The presence of a myxoid
stroma did not correlate with epigenetic subgrouping, as
both epigenetic subgroups contained some tumors with
and some without a mucin-r ich background. No immunohistochemical differences between the two epigenetic
subgroups were identified, and further studies are necessary to test potential immunohistochemical surrogates
for segregating the two epigenetic subgroups, perhaps

utilizing the list of most differentially methylated genes
as a starting point (Tables S1 and S2). Analysis of patient
outcomes demonstrated worse progression-free survival
of Group B tumors relative to Group A tumors (median
PFS of 4.5 vs. 49 months, respectively), although the cohort size of this study is small and this finding requires
further confirmation in larger patient cohorts.
Notably, one of the four tumors that we assigned as
belonging to Group B (CREM #1 located in the spinal
cord of a 15-year-old female harboring EWSR1-CREM
fusion) demonstrated a somewhat divergent epigenetic
profile relative to the other three tumors within Group B
by both unsupervised hierarchical clustering (Figure 1A)
and tSNE dimensionality reduction (Figure 4). Despite
being in closer proximity to the reference cluster of CCS
on the tSNE plot, this tumor CREM #1 more closely
grouped with the other Group B tumors than CCS
by unsupervised hierarchical clustering (Figure 6A),
demonstrated hypermethylation of the MITF locus similar to other Group B tumors (Figure 6B), and lacked expression of melanocytic protein markers similar to other
Group B tumors (Table 4). Whether this solitary tumor
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F I G U R E 5 Epigenetic comparison of Group A intracranial mesenchymal tumors with FET-CREB fusion to angiomatoid fibrous
histiocytoma (AFH) of extracranial soft tissue. (A) Unsupervised hierarchical clustering of DNA methylation data showing segregation of the
16 Group A tumors from 8 reference cases of angiomatoid fibrous histiocytoma arising in extracranial soft tissue. Differentially methylated
genomic regions are annotated in Tables S6 and S7. (B) Differential methylation-based gene ontology analysis for Group A intracranial
mesenchymal tumors versus AFH of extracranial soft tissue, represented in a bar plot of −log10 p values for the most differentially methylated
gene networks

in our cohort is representative of epigenetic heterogeneity amongst Group B tumors or alternatively might represent a third distinct epigenetic subgroup of intracranial
mesenchymal tumors with FET-CREB fusion remains
uncertain. Future studies with larger patient cohorts
are necessary to reveal the full biologic spectrum and
clinically relevant subgrouping of these tumors. Overall
however, our finding of at least two distinct epigenetic
subgroups is similar to a recent report of epigenomic
characterization performed on a cohort of 11 primary
intracranial mesenchymal tumors with FET-CREB fusion, which identified that 6 of their 11 cases formed a
unique epigenetic cluster, whereas the other 5 cases were
epigenetically heterogeneous and unclassifiable [27].
For the time being, we believe that these are best considered as two epigenetic subtypes under the single overarching tumor type ‘intracranial mesenchymal tumor,
FET-CREB fusion-positive’. This conclusion is based on
our cohort of 20 tumors and the fact that there were not
statistically significant differences in histomorphology
(including stromal mucin content), immunophenotype,
fusion partner, patient age, sex, tumor anatomic location, or other features between the two epigenetic subgroups that would enable definitive segregation into two
or more distinct tumor types/entities at this point beyond
epigenomic signature. However, future studies encompassing larger patient cohorts may potentially indicate

and be used to provide support that these actually represent two or more distinct tumor types.
There has been ongoing uncertainty as to the relationship of tumors diagnosed as “intracranial angiomatoid fibrous histiocytoma” and those diagnosed as
“intracranial myxoid mesenchymal tumor”, and we previously proposed the unifying terminology of “intracranial mesenchymal tumor, FET-CREB fusion-positive”
for this group of neoplasms [5], which has been adopted
in the 5th edition of the WHO Classification of Tumors
of the Central Nervous System [1]. There has also been
ongoing uncertainty as to the relationship of these intracranial mesenchymal tumors with FET-CREB fusion
to meningiomas, as well as to the myriad of extracranial neoplasms harboring identical FET-CREB fusions,
which include angiomatoid fibrous histiocytoma, clear
cell sarcoma of soft tissue, clear cell sarcoma of the gastrointestinal tract, primary pulmonary myxoid sarcoma,
hyalinizing clear cell carcinoma of the salivary gland,
and a subset of malignant mesotheliomas lacking BAP1
and NF2 alterations [6–16]. Our epigenomic profiling
has shed substantial light on these issues that we discuss
herein.
First, our epigenomic data, together with the differential immunophenotype (e.g. lack of somatostatin receptor 2A [SSTR2A] expression, presence of desmin and
MUC4 expression), further differentiate intracranial
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F I G U R E 6 Epigenetic comparison of Group B intracranial mesenchymal tumors with FET-CREB fusion to clear cell sarcoma (CCS) of
extracranial soft tissue. (A) Unsupervised hierarchical clustering of DNA methylation data showing segregation of the 4 Group B tumors from
7 reference cases of clear cell sarcoma arising in extracranial soft tissue. Differentially methylated genomic regions are annotated in Tables S9
and S10. (B) Visualization of DNA methylation status at individual CpG sites (vertical green bars) at the MITF gene locus in the 4 Group B
tumors and 7 reference cases of CCS arising in extracranial soft tissue. All but one CpG site demonstrate substantial hypermethylation in the
Group B tumors, whereas most all CpG sites are unmethylated or hypomethylated in the CCS tumors. (C) Immunohistochemistry for MITF,
a transcription factor robustly expressed in CCS of soft tissue, as well as the other melanocytic markers HMB45 and Melan A, was negative
in all four Group B intracranial mesenchymal tumors with FET-CREB fusion. (D) Differential methylation-based gene ontology analysis for
Group B intracranial mesenchymal tumors versus CCS of extracranial soft tissue, represented in a bar plot of −log10 p values for the most
differentially methylated gene networks

mesenchymal tumors with FET-CREB fusion from meningiomas. However, we cannot exclude a shared cell of origin with meningiomas and/or meningeal solitary fibrous
tumors, potentially with epigenetic reprogramming driven
by the FET-CREB fusion causing the unique epigenetic
signature we found for this tumor type. Further studies are
required to define the specific cell of origin of these tumors, which we speculate to be a mesenchymal cell within
the meningeal covering of the brain. In support of this hypothesis, electron microscopy performed on intracranial

mesenchymal tumors with FET-CREB fusion has reportedly demonstrated ultrastructural features overlapping
with those typically seen in meningioma including interdigitating cell processes lined by well-formed desmosomes
and abundant extra-cellular collagen [27].
Second, as both epigenetic subgroups of intracranial
mesenchymal tumors with FET-CREB fusion contained
some tumors with a mucin-r ich stroma resembling “intracranial myxoid mesenchymal tumor” (or the so-
called “myxoid variant of AFH”) and also some with a

INTRACRANIAL MESENCHYMAL TUMOR, FET-CREB FUSED

mucin-poor stroma resembling “intracranial angiomatoid fibrous histiocytoma”, we conclude that these represent histologic variants of a single overarching tumor
type. We believe these results further substantiate the
unifying nosology of ‘intracranial mesenchymal tumor,
FET-
CREB fusion-
positive’. However, as previously
discussed, future studies encompassing larger patient
cohorts may potentially indicate and be used to provide
support that these epigenetic subgroups among intracranial mesenchymal tumors with FET-CREB fusions
actually represent two or more distinct tumor types.
Lastly, we have compared the epigenomic signature of
these intracranial mesenchymal tumors with two of the
extracranial neoplasms harboring identical FET-CREB
fusions for which DNA methylation profiles have been
generated to date. Our results reveal that intracranial
mesenchymal tumors with FET-CREB fusion are epigenetically distinct from both AFH of extracranial soft
tissue and CCS of soft tissue. Given both their distinct
epigenetic signature and divergent anatomic site of origin, our results provide further evidence that these tumors should be considered a distinct tumor entity, and not
merely regarded as intracranial occurrence of these two
sarcomatous neoplasms which characteristically occur
in extracranial soft tissue, most often in the extremities.
This is particularly true for CCS of soft tissue, given the
differential methylation of the MITF gene we identified
and the absence of melanocytic marker expression in intracranial mesenchymal tumors with FET-CREB fusion.
In summary, we have epigenetically characterized
intracranial mesenchymal tumors with FET-CREB fusion, revealing at least two distinct epigenetic subgroups
with potential prognostic significance. Our epigenomic
results also provide substantial clarification for the ontology of these unique intracranial neoplasms.
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